Loading Filters
Showing 1–3 of 3 results
-
-
-
Research |
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
- C Buske
- , E Hoster
- , M Dreyling
- , H Eimermacher
- , H Wandt
- , B Metzner
- , R Fuchs
- , J Bittenbring
- , B Woermann
- , K Hohloch
- , G Hess
- , W-D Ludwig
- , J Schimke
- , S Schmitz
- , M Kneba
- , M Reiser
- , U Graeven
- , W Klapper
- , M Unterhalt
- & W Hiddemann
Leukemia 23 , 153–161
